Against rebound

Pancreatic cancer: Genome-wide analysis reveals new strategies

For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant.

This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression. To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent. The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.

pancreatic cancer cells
Pancreatic cancer cells (blue) growing as a sphere encased in membranes (red).
Source: National Cancer Institute

In a new paper publishing in the online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies — and thus vulnerabilities — of pancreatic cancer stem cells. 

Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or RORγ, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models. “These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, RORγ emerged as a key regulator. RORγ rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth. “Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.

portrait of tannishtha reya
Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine.
Source: UC San Diego Health

Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.” In particular, she said the discovery of RORγ‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting RORγ have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”


Source: University of California San Diego School of Medicine

05.04.2019

Read all latest stories

Related articles

Photo

Cellular recycling

Can autophagy stop cancer before it starts?

Just as plastic tips protect the ends of shoelaces and keep them from fraying when we tie them, molecular tips called telomeres protect the ends of chromosomes and keep them from fusing when cells…

Photo

Large study

Five novel genetic changes linked to pancreatic cancer risk

In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and…

Photo

Genetic engineering

CAR-T: Landmark cancer study sheds new light on immunotherapy

Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system…

Related products

Eppendorf - Mastercycler nexus X2

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG
Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
Eppendorf - BioSpectrometer fluroescence

Research use only (RUO)

Eppendorf - BioSpectrometer fluroescence

Eppendorf AG
Eppendorf - μCuvette G1.0

Research use only (RUO)

Eppendorf - μCuvette G1.0

Eppendorf AG
Orion Diagnostica Oy - Orion GenRead

Amplification

Orion Diagnostica Oy - Orion GenRead

Orion Diagnostics Oy